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Background: Researchers often group various HPV types into composite measures based on vaccine subtypes,
oncogenic potential, or phylogenetic position. Composite prevalence estimates based on PCR genotyping assay
results have been calculated to assess HPV infection burden and to monitor HPV vaccine effectiveness. While
prevention and intervention strategies can be made based on these prevalence estimates, the discussion on how
well these prevalence estimates measure the true underlying infection burdens is limited.
Methods: A simulation study was conducted to evaluate accuracy of using composite genotyping assay results to
monitor HPV infection burden. Data were generated based on mathematical algorithms with prespecified type-specific
infection burdens, assay sensitivity, specificity, and correlations between various HPV types. Estimated-to-true prevalence
rate ratios and percent reduction of vaccine types were calculated.
Results: When “true” underlying type-specific infection burdens were prespecified as the reported prevalence in U.S.
and genotyping assay with sensitivity and specificity (0.95, 0.95) was used, estimated-to-true infection prevalence ratios
were 2.35, 2.29, 2.18, and 1.46, for the composite measures with 2 high-risk vaccine, 4 vaccine, 14 high-risk and 37 HPV
types, respectively. Estimated-to-true prevalence ratios increased when prespecified “true” underlying infection burdens
or assay specificity declined. When prespecified “true” type-specific infections of HPV 6, 11, 16 and 18 were reduced by
50%, the composite prevalence estimate of 4 vaccine types only decreased by 17% which is much lower than 48%
reduction in the prespecified “true” composite prevalence.
Conclusions: Composite prevalence estimates calculated based on panels of genotyping assay results generally
over-estimate the “true” underlying infection burdens and could under-estimate vaccine effectiveness. Analytical
specificity of genotyping assay is as or more important than analytical sensitivity and should be considered in
selecting assay to monitor HPV.
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Infection with human papillomaviruses (HPVs) can
cause warts and various forms of carcinoma in the
cervix, anus, vagina, vulva, head and neck in women
and men [1]. More than 120 types of HPV have been
identified according to DNA genomes [1,2]. Re-
searchers have classified and grouped these HPV
types by their association with a variety of clinicalCorrespondence: clin@cdc.gov
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unless otherwise stated.conditions (i.e., cervical cancer, warts), phylogenetic pos-
ition, and types related to vaccines [1,3] to form composite
measures. Polymerase chain reaction (PCR-based) DNA
genotyping tests can detect the existence of small amount
of virus and have been considered as the “gold standard”
to detect infectious organisms [4,5]. Prevalence estimates
based on one or a panel of PCR genotyping test results has
been used for research purposes in numerous epidemi-
ology/clinical studies to assess the burden of HPV infec-
tions [6-10] and vaccine effectiveness [11-13]. While
prevention and intervention strategies can be made based
on these prevalence estimates, research on how well theseOpen Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
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lying infection burden is limited.
Various factors could affect accuracy of composite preva-
lence estimates. Depending on the classification, the num-
ber of HPV types included in the composite measures
could be different. Since HPV type-specific infections share
the same risk factors (i.e., sexual lifestyle, age, etc.) and sub-
jects with weaker immune systems are more likely to get
infected or stay infected, HPV type-specific infections are
likely to be correlated and could result in coinfection with
more than one HPV type [14,15]. In another word, the
probability of getting infected or detecting any given HPV
type is greater among individuals who are currently posi-
tive for at least one other HPV type. In addition, the under-
lying infection prevalence of various HPV types can be
different by study population (i.e., different age groups and
geographic regions) or change over time [16,17]. Further-
more, more than 20 in-house or commercial HPV geno-
typing assays (e.g., Linear Array, INNO-LiPA) have been
used to detect HPV infections [13,16,18,19]. Analytical sen-
sitivity and specificity of these genotyping assays can vary
greatly for various reasons (e.g., primer set, reaction condi-
tion, laboratory techniques of personnel, etc.) [18-20] and
result in different composite prevalence estimates.
Challenges to evaluate accuracy of prevalence estimates
include not knowing the true values of underlying type-
specific infection burdens, low feasibility to recruit subjects
from various regions with various levels of infection bur-
dens and to test numerous assays for comparisons. To
overcome these challenges, we performed a Monte Carlo
simulation study to evaluate composite prevalence esti-
mates. The simulation approach allows us to have data
with various levels of known prespecified “true” underlying
type-specific infection burdens and genotyping test results
based on the prespecified assay performance so the preva-
lence estimates calculated based on type-specific assay re-
sults can be compared to the pre-specified “true”
underlying infection burden. Monte Carlo simulation ap-
proach has been widely used in statistics, physics, finance,
economics and engineering to evaluate the impact of vari-
ous factors on complex systems/processes and identify an
optimal system design/process [21-25]. For this study, we
are interested in examining accuracy of the composite
prevalence estimates based on panels of PCR genotyping
assay results and the impacts of various factors.
Method
Simulation settings
A simulation study was conducted to evaluate compos-
ite prevalence estimates calculated based on panels of
PCR genotyping assay results. Data were generated
using mathematical algorithms extended from Lin et al.
[26] with prespecified values of “true” underlying type-
specific prevalence, PCR genotyping assay sensitivityand specificity and correlations among HPV types. The
infectious statuses were assigned based on the prespe-
cified type-specific prevalence; and the genotyping test
results were obtained based on the type-specific infec-
tious status, genotyping sensitivity and specificity. Each
data set included the known “true” type-specific infec-
tion statuses and genotyping assay results so the preva-
lence estimates could be calculated to compare to the
prespecified “true” infection burdens. Without loss of
generality, the total number of subjects was set to be
4,000 and correlations between HPV types were set to
be 0.05 which was the average value of 666 pairwise
correlations of 37 HPV genotyping test results in the
2003–2006 National Health and Nutrition Examination
Survey (NHANES). For each scenario, 500 data sets
were generated. Mean and standard deviation of the
“true” and estimated composite prevalence of 500 data
sets were calculated. Mathematical algorithms related
to the simulation setup are given in the Appendix.
Two different levels of infection burdens were consid-
ered. For the first setting, the “true” underlying type-
specific infection burdens were prespecified as the
reported 37 different HPV prevalence of females, aged
14–59, 2003–2006, in the U.S. (Figure 1) [7]. For the
second setting, the “true” underlying type-specific in-
fection burdens were prespecified as the reported 45
different HPV prevalence of females, aged 14 or older,
2008–2009 in the Northwest Territories (NWT),
Canada [9]. The reported type-specific prevalence in
the NWT, Canada was generally lower than in the U.S.
and the relative rates were also different (Figure 1).
Definition of true and estimated composite prevalence
Four composite outcome measures are defined as the
following: having HPV (37 types in the U.S. and 45 types
in Canada), having high-risk HPV (14 types in the U.S.
and 22 types in Canada), having vaccine type HPV (HPV
6, 11, 16 and 18), and having high-risk vaccine type
HPV (HPV 16, 18). HPV 16 and HPV 18 are generally
considered particularly high-risk genotypes and ac-
count for approximately 70% of invasive cervical can-
cers globally [27,28]. Quadrivalent HPV Vaccine
(HPV4, Gardasil) protects against HPV 6, 11, 16 and
18. Bivalent HPV (HPV2, Cervarix) protects against
HPV 16 and 18.
Prespecified “true” prevalence of each outcome meas-
ure is defined as the proportion of subjects with a
positive infection status. For each subject, based on the
pre-specified “true” type-specific infectious statuses, the
“true” composite positive infection status of the four
outcome measures is defined as having at least one HPV
type-specific infection of the 37 HPV types (45 HPV in
Canada), 14 high-risk types (22 high-risk in Canada), 4
vaccine types, and 2 high-risk vaccine types.
Figure 1 The reported type-specific prevalence of the U.S., 2003–2006 and the Northwest Territories (NWT), Canada, 2008–2009.
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as the proportion of subjects with positive composite test
results. For each subject, a positive test result of the four
outcome measure is defined as having at least one positive
of the 37 HPV (45 HPV in Canada), 14 high-risk (22 high-
risk in Canada), 4 vaccine, and 2 high-risk vaccine type-
specific results. To examine how well the composite preva-
lence estimate measures the “true” underlying composite
prevalence, for each outcome measure, estimated-to-true
prevalence ratio was calculated. A ratio greater than 1
means the composite prevalence estimate calculated based
on a panel of genotyping assay results over-estimates the
“true” underlying composite infection burden. The number
of false positives exceeds the number of false negatives. In
contrast, a ratio less than 1 means composite prevalence
estimate calculated based on a panel of genotyping assay
results underestimates the “true” underlying composite in-
fection burden. The number of false negatives exceeds the
number of false positives. The larger the ratio from 1, the
less accurate the composite prevalence estimate is.
To assess the effects of analytical sensitivity and specifi-
city of genotyping assay on composite prevalence esti-
mates, the initial values of PCR genotyping assay sensitivity
and specificity were set to be equal (0.95, 0.95) to reflect
the well-performed Linear Array test and then the assay
performance was varied. To examine the effect of genotyp-
ing assay specificity, assay sensitivity was held unchanged
and specificity was reduced from 0.95 to 0.90, 0.85 and
0.80. Similarly, to examine the effect of genotyping assay
sensitivity, assay specificity was held unchanged and sensi-
tivity was reduced from 0.95 to 0.90, 0.85 and 0.80.
To examine how well the composite prevalence estimates
measured intervention effectiveness, for demonstration
purposes, assuming the pre-specified “true” type-specific
prevalence of the 4 vaccine types (HPV 6, 11, 16 and 18)
were reduced by 50%. Percent reductions of composite
prevalence estimates of 4 vaccine types and 2 high-risk vac-
cine types (HPV 16, 18) were calculated and compare tothe reductions in the prespecified “true” underlying com-
posite prevalence.
To examine the effects of levels of underlying type-
specific infection burdens and number of HPV types in
the composite measure on the composite prevalence
estimates, prevalence estimates of the four outcome
measures from the U.S. scenarios were compared to
those estimates from the NWT, Canada scenarios. The
reported type-specific HPV prevalence in the NWT,
Canada was generally lower than in the U.S. and the
relative rates were also different (Figure 1). In the U.S.
scenarios, there are 37 HPV types and 14 high-risk
types. In the NWT, Canada, there are 45 HPV types and
22 high-risk types.
To examine the effects of correlations between differ-
ent HPV types on composite prevalence estimates, the
correlations between different HPV types were varied
from 0, 0.05, 0.1, 0.2, 0.3 and 0.4. The “true” underlying
type-specific infections were prespecified as the reported
prevalence in the U.S. and type-specific assay sensitivity
and specificity were set to be (0.95, 0.95). “True” com-
posite prevalence, estimated composite prevalence and
estimated-to-true prevalence ratios of 37 HPV, 14 high-
risk HPV, 4 vaccine and 2 high-risk vaccine types were
calculated.
Results
Table 1(a,b) show the results of estimated composite
prevalence when the “true” type-specific infection bur-
dens are prespecified as the reported prevalence in the
U.S. When genotyping assay with sensitivity and specifi-
city (0.95, 0.95) is used, composite prevalence estimates
based on a panel of genotyping assay results generally
overestimate prespecified “true” composite infection
burden. As shown in Table 1, the estimated-to-true
prevalence rate ratios are 2.35, 2.29, 2.18 and 1.46 for
composite measures with 2, 4, 14 and 37 HPV types,
respectively.






















a: Sensitivity ≤ Specificity
Sen.= 0.95 Sen. = 0.90 Sen. = 0.85 Sen. = 0.80
Spe.= 0.95 Spe. = 0.95 Spe. = 0.95 Spe. = 0.95
2 Baseline 0.064 (0.004) 0.151 (0.006) 2.359 0.148 (0.005) 2.313 0.146 (0.006) 2.281 0.143 (0.005) 2.234
Reduced 0.032 (0.003) 0.125 (0.005) 3.906 0.123 (0.005) 3.843 0.121 (0.005) 3.781 0.120 (0.005) 3.750
% red. 50 17.2 16.9 17.1 13.9
4 Baseline 0.120 (0.005) 0.275 (0.007) 2.292 0.269 (0.007) 2.242 0.264 (0.007) 2.200 0.260 (0.007) 2.167
Reduced 0.062 (0.004) 0.229 (0.007) 3.694 0.227 (0.006) 3.661 0.224 (0.007) 3.613 0.222 (0.006) 3.581
% red. 48 16.7 15.6 15.2 14.6
14 Baseline 0.282 (0.007) 0.616 (0.007) 2.184 0.609 (0.008) 2.160 0.603 (0.008) 2.138 0.596 (0.008) 2.113
Reduced 0.259 (0.007) 0.604 (0.008) 2.332 0.599 (0.008) 2.313 0.593 (0.008) 2.290 0.587 (0.008) 2.266
% red. 8.2 1.9 1.6 1.7 1.5
37 Baseline 0.617 (0.008) 0.904 (0.004) 1.465 0.900 (0.005) 1.459 0.895 (0.005) 1.451 0.891 (0.005) 1.444
Reduced 0.596 (0.008) 0.899 (0.005) 1.508 0.895 (0.005) 1.502 0.891 (0.005) 1.495 0.887 (0.005) 1.488
% red. 3.4 0.5 0.6 0.4 0.4
b: Sensitivity ≥ Specificity
Sen. = 0.95 Sen. = 0.95 Sen. = 0.95 Sen. = 0.95
Spe. = 0.95 Spe. = 0.90 Spe. = 0.85 Spe. = 0.80
2 Baseline 0.064 (0.004) 0.151 (0.006) 2.359 0.237 (0.007) 3.703 0.318 (0.007) 4.969 0.394 (0.008) 6.156
Reduced 0.032 (0.003) 0.125 (0.005) 3.906 0.213 (0.006) 6.656 0.297 (0.007) 9.281 0.374 (0.008) 11.688
% red. 50 17.2 10.1 6.6 5.1
4 Baseline 0.120 (0.005) 0.275 (0.007) 2.292 0.409 (0.008) 3.408 0.525 (0.008) 4.375 0.621 (0.008) 5.175
Reduced 0.062 (0.004) 0.229 (0.007) 3.694 0.374 (0.008) 6.033 0.496 (0.008) 8.000 0.598 (0.008) 9.645
% red. 48 16.7 8.6 5.5 3.7
14 Baseline 0.282 (0.007) 0.616 (0.008) 2.184 0.797 (0.006) 2.826 0.895 (0.005) 3.174 0.947 (0.004) 3.358
Reduced 0.259 (0.006) 0.604 (0.008) 2.332 0.792 (0.006) 3.058 0.892 (0.005) 3.444 0.945 (0.004) 3.649












Table 1 Composite prevalence estimates when the “true” underlying type-specific infection burden is pre-specified as the reported prevalence in the U.S.
(Continued)
37 Baseline 0.617 (0.008) 0.904 (0.004) 1.465 0.975 (0.002) 1.580 0.993 (0.001) 1.609 0.998 (0.007) 1.515
Reduced 0.596 (0.008) 0.899 (0.005) 1.508 0.974 (0.003) 1.634 0.993 (0.001) 1.666 0.998 (0.007) 1.674
% red. 3.4 0.5 0.1 0 0
*2: high-risk vaccine types (HPV 16, 18); 4: vaccine types (HPV 6, 11, 16, 18); 14: high-risk types (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68); 37: HPV types (HPV 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51,
52, 53, 54, 55, 56, 58, 59,61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73, 81, 82, 83, 84, 89, IS39).
§Pre-specified type-specific prevalence at baseline: HPV 6 = 0.028, HPV11 = 0.034, HPV16 = 0.047, HPV18 = 0.019, HPV26 = 0.022, HPV31 = 0.015, HPV33 = 0.013, HPV35 = 0.023, HPV39 = 0.011, HPV40 = 0.018, HPV42 = 0.025,
HPV45 = 0.020, HPV51 = 0.041, HPV52 = 0.036, HPV53 = 0.058, HPV54 = 0.038, HPV55 = 0.024, HPV56 = 0.023, HPV58 = 0.014, HPV59 = 0.030, HPV61 = 0.040, HPV62 = 0.065, HPV64 = 0.002, HPV66 = 0.034, HPV67 = 0.013,
HPV68 = 0.016, HPV69 = 0.027, HPV70 = 0.020, HPV71 = 0.056, HPV72 = 0.012, HPV73 = 0.015, HPV81 = 0.027, HPV82 = 0.054, HPV83 = 0.041, HPV84 =0.048, HPV89 = 0.047, HPVIS39 = 0.014.
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ity is reduced, the results suggest that composite preva-
lence estimates are robust to decline of assay sensitivity.
As shown in Table 1a, when sensitivity is decreased from
0.95, to 0.90, 0.85, 0.80, composite prevalence estimates
do not change much and the estimated-to-true ratios re-
main similar. When genotyping assay sensitivity is held
unchanged and specificity is decreased from 0.95, to
0.90, 0.85, 0.80, composite prevalence estimates increase
and the estimated-to-true ratios become much larger
(Table 1b). The overestimating problem is alleviated
when the number of HPV types in the composite meas-
ure becomes larger.
Simulation results also suggest that the composite
prevalence estimates could under-estimate vaccine ef-
fectiveness (Table 1a,b). When the prespecified “true”
underlying type-specific prevalence of HPV 6, 11, 16 and
18 are reduced to 50% of the reported level and geno-
typing assay with sensitivity and specificity (0.95.0.95)
is used, the prevalence estimates of 2 high-risk vaccine
types and 4 vaccine types were only reduced by 17.2%
and 16.7%, respectively, which are much lower than
the 50% and 48% reduction in the prespecified infec-
tion burden.
Table 2(a,b) shows the results of estimated composite
prevalence when “true” type-specific prevalence is pre-
specified as the reported prevalence in the Northwest
Territories (NWT), Canada. Results suggest that the
magnitude of over-estimation is greater in the NWT,
Canada than in the U.S. due to lower HPV infection bur-
dens in Canada. In addition, increasing the number of
HPV types in the composite measure does not help
much to alleviate the over-estimating problem as in the
U.S. scenarios.
The results of sensitivity analysis for correlations are
given in Table 3. Results suggest that estimated-to-true
prevalence ratios are robust to the change of correlations
and the impact of correlations on the composite mea-
sures depends on the magnitude of correlations and the
number of HPV types in the composite measures. The
impact of correlations is limited when the number of
HPV types in the composite measure is relatively small
(e.g., 2, 4). Magnitude of decline in composite prevalence
estimates increases with increasing number of HPV
types in the composite measures (Table 3).
Discussion
Prevalence estimates based on one or panels of PCR geno-
typing assay results have been used to assess HPV infection
burdens and monitor vaccine effectiveness [11,29]. Since
true HPV infection burdens are often unknown, mathem-
atical algorithms with prespecified infection burdens and
assay performance were used to simulate various scenarios
to evaluate these composite prevalence estimates.PCR-based DNA genotyping tests can detect the exist-
ence of small amount of virus. The PCR process
includes denaturation, annealing and extension in each
PCR cycle. Each cycle approximately doubles the
amount of target viral DNA. Although PCR process is
labor-intensive and time consuming, PCR can theoretic-
ally produce one million copies from a single double-
stranded DNA molecule after 30 cycles. Analysis of the
amplification products can be done in different ways
including gel electrophoresis, dot blot or line strip
hybridization [30].
The initial values of PCR genotyping assay sensitiv-
ity and specificity were set to be equal to (0.95, 0.95)
in this simulation study to reflect a well-performed
Linear Array test. Roche Linear Array genotyping
assay is the commercialized version of a PCR test
which is designed to standardize the entire PCR
process and to detect 37 HPV types. LA is a qualita-
tive test and has been used for research purpose in
numerous epidemiological/clinical studies. It is also
the most widely-used assay by the labs of the World
Health Organization (WHO) HPV labNet to monitor
HPV vaccine effectiveness. When specimens are care-
fully handled and PCR procedures are strictly per-
formed according to protocol, analytical sensitivity
and specificity of Linear Array assay can reach (0.95,
0.95). The performance of in-house assays can have
greater variation since each of the many steps of the
PCR testing procedure can introduce important vari-
ability [18-20]. Factors associated with analytical sen-
sitivity and specificity of PCR testing include primer
selection, lab environment and reaction conditions,
performance of the DNA polymerase used in the reac-
tion, laboratory techniques of personnel and specimen
acquisition, handling and storage, etc. [30].
Type-specific HPV infections are considered to be
correlated in this simulation study because the risk
factors of getting infected by various HPV types are
similar and subjects with weaker immune systems are
more likely to get infected and/or stay infected. With-
out loss of generality, the correlations between HPV
types were set to be 0.05. This is the mean of 666
pairwise correlations calculated based on 37 Linear
Array genotyping test results collected in the 2003–
2006 National Health and Nutrition Examination Sur-
vey (NHANES). Although the values of pairwise cor-
relations varied from 0 to 0.3, eighty-five percent of
these pairwise correlations were somewhere between
0 and 0.1. In addition, the simulation results (Table 3)
suggest the effect of correlations on estimated-to-true
prevalence ratios is limited. The impact of correla-
tions on the composite prevalence depends on the
magnitude of correlations and the number of HPV
types in the composite measure. The higher the























a: Sensitivity ≤ Specificity
Sen. = 0.95 Sen. = 0.90 Sen. = 0.85 Sen. = 0.80
Spe. = 0.95 Spe. = 0.95 Spe. = 0.95 Spe. = 0.95
2 Baseline 0.053 (0.004) 0.142 (0.006) 2.676 0.140 (0.005) 2.642 0.138 (0.005) 2.604 0.135 (0.005) 2.547
Reduced 0.027 (0.003) 0.120 (0.005) 4.444 0.119 (0.005) 4.407 0.117 (0.005) 4.333 0.116 (0.005) 4.296
% red. 49.1 15.5 15.0 15.2 14.1
4 Baseline 0.064 (0.004) 0.231 (0.007) 3.609 0.229 (0.006) 3.578 0.226 (0.006) 3.531 0.224 (0.006) 3.500
Reduced 0.033 (0.003) 0.207 (0.006) 6.272 0.206 (0.006) 6.242 0.204 (0.006) 6.181 0.203 (0.007) 6.152
% red. 48.4 10.4 10.0 9.7 9.4
22 Baseline 0.216 (0.006) 0.701 (0.007) 3.245 0.697 (0.007) 3.227 0.694 (0.004) 3.213 0.690 (0.007) 3.194
Reduced 0.194 (0.006) 0.694 (0.007) 3.577 0.691 (0.007) 3.562 0.687 (0.007) 3.541 0.684 (0.007) 3.526
% red. 10.2 0.9 0.9 1.0 0.9
45 Baseline 0.287 (0.007) 0.841 (0.006) 2.930 0.839 (0.006) 2.923 0.836 (0.006) 2.913 0.834 (0.006) 2.906
Reduced 0.265 (0.007) 0.838 (0.006) 3.162 0.835 (0.006) 3.151 0.833 (0.006) 3.143 0.831 (0.006) 3.136
% red. 7.6 0.4 0.5 0.4 0.4
b: Sensitivity ≥ Specificity
Sen. = 0.95 Sen. = 0.95 Sen. = 0.95 Sen. = 0.95
Spe. = 0.95 Spe. = 0.90 Spe. = 0.85 Spe. = 0.80
2 Baseline 0.052 (0.004) 0.142 (0.006) 2.731 0.229 (0.006) 4.404 0.311 (0.007) 5.981 0.387 (0.008) 7.442
Reduced 0.027 (0.003) 0.120 (0.005) 4.444 0.209 (0.007) 7.74 0.293 (0.007) 10.85 0.371 (0.008) 13.74
% red. 49.1 15.5 8.7 5.8 4.1
4 Baseline 0.064 (0.004) 0.231 (0.007) 3.609 0.375 (0.007) 5.859 0.497 (0.008) 7.766 0.599 (0.008) 9.359
Reduced 0.033 (0.003) 0.207 (0.006) 6.272 0.356 (0.008) 10.78 0.482 (0.009) 14.61 0.588 (0.008) 17.82
% red. 48.4 10.4 5.1 3.0 1.8
22 Baseline 0.216 (0.007) 0.701 (0.007) 3.245 0.883 (0.005) 4.088 0.954 (0.003) 4.417 0.983 (0.002) 4.551












Table 2 Composite prevalence estimates when the “true” underlying type-specific infection burden is pre-specified as the reported prevalence in the
Northwest Territories, Canada (Continued)
% red. 10.2 0.9 0.2 0 0.1
45 Baseline 0.288 (0.007) 0.841 (0.006) 2.920 0.961 (0.003) 3.337 0.990 (0.002) 3.438 0.997 (0.001) 3.462
Reduced 0.265 (0.007) 0.838 (0.006) 3.162 0.960 (0.003) 3.623 0.990 (0.002) 3.736 0.997 (0.001) 3.762
% red. 7.6 0.4 0.1 0 0
*2: high-risk vaccine types(HPV 16, 18); 4: vaccine types (HPV 6, 11, 16, 18); 23: high-risk types (HPV 16, 18, 26, 30, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, 68, 69, 70, 73, 82, 85); 45: any types (HPV 6, 11, 13, 16,
18, 26, 30, 31, 32, 33, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 67, 68, 69, 70, 71, 72, 73, 74, 81, 82, 83, 84, 85, 86, 87, 89, 90, 91).
§Pre-specified type-specific prevalence at baseline:HPV6 = 0.009, HPV11 = 0.003, HPV13 = 0.001, HPV16 = 0.041, HPV18 = 0.013, HPV26 = 0, HPV30 = 0.002, HPV31 = 0.021, HPV32 = 0.001, HPV33 = 0.007, HPV35 =
0.007, HPV39 = 0.016, HPV40 = 0.005, HPV42 = 0.013, HPV43 = 0.002, HPV44 = 0.003, HPV45 = 0.015, HPV51 = 0.016, HPV52 = 0.014, HPV53 = 0.005,HPV54 = 0.008, HPV56 = 0.010, HPV58 = 0.013, HPV59 = 0.012,
HPV62 = 0.016, HPV66 = 0.019, HPV67 = 0.013, HPV68 = 0.003, HPV69 = 0.003, HPV70 = 0.011, HPV72 = 0.007, HPV73 = 0.005, HPV74 = 0.007, HPV81 = 0.007, HPV82 = 0.002, HPV83 = 0.007, HPV84 = 0.004, HPV85 =
0.003, HPV89 = 0.010, HPV90 = 0.004, HPV86 = 0.004, HPV87 = 0.001, HPV91 = 0.001, HPV61 = 0.001, HPV71 = 0.












Table 3 Sensitivity analysis for correlations

































0 0.064 0.151 2.36 0.121 0.279 2.30 0.293 0.647 2.23 0.663 0.947 1.43
0.05 0.064 0.151 2.36 0.121 0.275 2.27 0.282 0.616 2.19 0.617 0.904 1.47
0.1 0.064 0.151 2.36 0.119 0.269 2.26 0.271 0.584 2.15 0.576 0.861 1.49
0.2 0.063 0.147 2.33 0.115 0.255 2.22 0.247 0.526 2.13 0.501 0.776 1.55
0.3 0.062 0.144 2.32 0.110 0.242 2.20 0.223 0.473 2.12 0.436 0.695 1.59
0.4 0.061 0.141 2.31 0.104 0.228 2.19 0.200 0.423 2.12 0.376 0.615 1.63
*2: high-risk vaccine types (HPV 16, 18); 4: vaccine types (HPV 6, 11, 16, 18); 14: high-risk types (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68); 37: HPV types (HPV 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51,
52, 53, 54, 55, 56, 58, 59,61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73, 81, 82, 83, 84, 89, IS39).
Pre-specified type-specific prevalence: HPV 6 = 0.028, HPV11 = 0.034, HPV16 = 0.047, HPV18 = 0.019, HPV26 = 0.022, HPV31 = 0.015, HPV33 = 0.013, HPV35 = 0.023, HPV39 = 0.011, HPV40 = 0.018, HPV42 = 0.025,
HPV45 = 0.020, HPV51 = 0.041, HPV52 = 0.036, HPV53 = 0.058, HPV54 = 0.038, HPV55 = 0.024, HPV56 = 0.023, HPV58 = 0.014, HPV59 = 0.030, HPV61 = 0.040, HPV62 = 0.065, HPV64 = 0.002, HPV66 = 0.034, HPV67 =
0.013, HPV68 = 0.016, HPV69 = 0.027, HPV70 = 0.020, HPV71 = 0.056, HPV72 = 0.012, HPV73 = 0.015, HPV81 = 0.027, HPV82 = 0.054, HPV83 = 0.041, HPV84 = 0.048, HPV89 = 0.047, HPVIS39 = 0.014.
Pre-specified genotyping assay sensitivity = 0.95 and specificity = 0.95.
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likely co-infections would occur. Therefore, the higher
the co-infection rate, the lower the composite preva-
lence will be.
When comparing results from the U.S. scenarios with
those from the NWT, Canada, although results are gener-
ally consistent, the magnitude of over-estimation is more
severe in the NWT, Canada scenarios. This is because the
pre-specified “true” underlying type-specific infection bur-
den is generally lower in the NWT, Canada and the chance
of getting false positive increases. Assay specificity become
even more important for getting accurate prevalence esti-
mates. Unlike the US scenario, increasing number of HPV
types in the composite measures does not always help to
ease the overestimating problem in the NWT, Canada. It is
because in the U.S. scenarios, the type-specific infection
burdens of newly-added HPV types are at similar or higher
levels than those already in the composite measure. In the
NWT, Canada, the type-specific infection burdens of
newly-added types are much lower than those already in
the composite measure (Figure 1), therefore, the magni-
tude of false positive rates increased is much greater.
In the context of monitoring HPV infection burden, the
focus has been given to assay analytical sensitivity to detect
the existence of HPV infections. There has been a ten-
dency either to develop a new testing technique or to mod-
ify existing techniques to increase analytical sensitivity to
detect HPV. Studies suggest that increasing analytical sen-
sitivities of HPV detection has reveals that the HPV preva-
lence is higher than previously suggested [31,32]. In
contrast to previous studies, the simulation results suggest
that prevalence estimates based on PCR genotyping assay
results generally overestimate the true infection burden;
genotyping assay sensitivity has limited effect on the com-
posite prevalence estimates; and the decline in specificity is
more influential. When assay specificity declines, false
positive rates increase and the problem of overestimating
becomes more severe. Particularly, when underlying type-
specific infection rates are low, for each HPV type, small
reductions in genotyping assay specificity results in a high
number of subjects with false positive results. Therefore,
eliminating factors which might cause false positives (i.e.,
contamination introduced through reagents, laboratory
disposables or equipment including carry-over contamin-
ation between tests or sample-to-sample contamination,
etc.) to increase assay specificity is important.
Since the introduction of the HPV vaccine in 2006, more
nations are now monitoring HPV infection as an earlier in-
dication of vaccine effectiveness [11,12,29]. More than 20
types of in-house or commercial assays have been devel-
oped to detect HPV infections and the performance of
these assays varies [13,16,18,20]. Also, true underlying in-
fection burdens vary by geographic regions, age groups
[16,17] and can change over time. We need to be awarethat accuracy of prevalence estimates based on panels of
genotyping assay results can vary by true underlying infec-
tion burden, genotyping assay performance and number of
HPV types included in the composite measure. For geo-
graphic regions or subpopulations with relatively low infec-
tion burden, in general, prevalence estimates overestimate
true underlying infection burden and could underestimate
vaccine effectiveness. Also, we need to understand that the
impact of genotyping assay specificity is as or more import-
ant than sensitivity and should be considered in selecting a
genotyping assay to monitor HPV infections. Particularly,
subjects with positive HPV detected by PCR in research
studies generally are not informed or referred to have col-
poscopy, since persistent infection of HPV high-risk types
is the pivotal event in the development of cervical cancer
and most of HPV detected can be cleared without treat-
ment in about two years. In addition, on the population
level, from the point of view of infectiousness, population
prevalence calculations based on PCR results could over-
estimate true infectiousness burden, since a very tiny
amount of DNA detected by PCR is likely not infectious
and may just represent a past infection. Furthermore, la-
boratory guidelines or policies leading to more standard-
ized assay performance between different laboratories are
necessary for combining data from different sites to esti-
mate vaccine effectiveness or compare infection burden at
various geographic regions.
In this study, we simulated various scenarios to
evaluate composite prevalence estimates based on
PCR genotyping assay results. Although it is not pos-
sible to consider all levels of infection burden or PCR
genotyping assay performance, this simulation study is
able to examine the impact of true infection burden
and assay sensitivity and specificity on the accuracy of
composite prevalence estimates. Estimated-to-true
prevalence ratios were used to examine how well the
prevalence estimates based on genotyping assay re-
sults measure the true underlying infection burden.
One limitation is the ratio does not provide informa-
tion to distinguish true and false positive rates. True
and false positive rates depend on the type-specific in-
fection burden and genotyping assay sensitivity and
specificity. Although the simulation result suggest that
increasing number of HPV types in the composite
measure could improve the accuracy of composite
prevalence, HPV types are grouped to form composite
measures based on their association with a variety of
clinical conditions, phylogenetic position or types re-
lated to vaccines and may not be varied. Cross-
reaction is not discussed in this manuscript since the
chance of cross-reaction occurrence when applying
PCR testing technique is relatively low. In addition,
bias which can be introduced due to study design (i.e.,
sampling strategy, confounders) is not discussed in
Lin BMC Infectious Diseases  (2015) 15:123 Page 11 of 12this manuscript. Having a good sample representing
the target population is very important. Since PCR
genotyping assay results have limited clinical utility,
future studies can be conducted to investigate incorp-
orating HPV clinical tests (i.e.,Digene HC2 or Cobas
test) to monitor HPV infections.
Conclusions
Composite prevalence estimates calculated based on
panels of genotyping assay results generally overestimate
the true infection burden and could underestimate ef-
fectiveness. Analytical specificity of genotyping assay is
as or more important than sensitivity and should be
considered in selecting assay to monitor HPV.
Appendix
Suppose that n independent subjects, i = 1,2,…,n, are
in the study. For each subject, i, K various HPV
types, j = 1,2,….k, are tested. Let δj denote the true
type-specific prevalence for the j-th HPV type and
δjs = (δ1, δ2,…,δj,…,δk) be the true type-specific
prevalence for k various types. The true type-specific
prevalence rates are considered to be different. α and
β are the analytical sensitivity and specificity of
genotyping assays. Genotying assay performance is
considered to be the same for all types. Let Ti1, Ti2,..
Tij,…,Tik be the genotyping assay results of k various
types of the i-th subject and Tij be the j-th type-
specific result of the i-th subject. Let Di1, Di2,…,Dij,
…, Dik be the true infection status of k various types
of the i-th subject.
Similar to the latent approach in Lin et al. for sub-
unit diagnostic tests [26], we assume that true type-
specific infection status and genotyping test result of
k various types, (Di1,Ti1, … Dij, Tij, …, Dik,Tik), is a
manifestation of a multivariate normal latent vector
(Yi1, Zi1,…Yij, Zij,…, Yik, Zik) with mean zero and cor-
relation matrix ∑k, a 2 k by 2 k matrix. Without loss
of generality, the variance of Yij and Zij are assumed
to be one. For each type, j, Yij and Zij are latent vari-
ables with thresholds of pj and qj for the binary vari-
ables, Dij and Tij, respectively. In another words, Yij
and Zij are dichotomized as follows:
Dij ¼ 1 if Y ij≥pj0 if Y ij < pj;

Tij ¼ 1 if Zij≥qj0 if Zij < qj:

The threshold values of pj can be expressed as func-
tions of the true infection rate of the j-th type, δj, and
the threshold values of qj can be expressed as functions
of the true type-specific prevalence of the j-th type, δj,
assay sensitivity, α, and specificity, β, as follows:pj ¼ Φ−1 δj
 
and qj ¼ Φ−1 αδ j þ 1−βð Þ 1−δj
  
;
where ΦΟ is the standard cumulative univariate nor-
mal distribution function. It is because
P Y ij≥pj
 
¼ P Dij ¼ 1




¼ P Tij ¼ 1
 
¼ P Tij ¼ 1;Dij ¼ 1
 þ P Tij ¼ 1;Dij ¼ 0 
¼ PðTij ¼ 1 Dij ¼ 1
 P Dij ¼ 1 þ PðTij ¼ 1 Dij ¼ 0 
P Dij ¼ 0
 
¼ αδj þ 1−βð Þ 1−δj
 
:
Furthermore, α and pj, and qj (and thus α, β, and δj)
also determine the correlation between Yij and Zij, since
α ¼ PðTij ¼ 1 Dij ¼ 1
  ¼ PðY ij≥pj;Zij≥qjÞ
PðY ij≥pjÞ
¼ 1−ΦðpjÞ−ΦðqjÞ þΦ2ðpj; qj; ϱÞ
1−ΦðpjÞ
where φ2 (y,z;ϱ) is the cumulative distribution function
of bivariate normal random vector with means of zero,
variance of 1 and correlation of ϱ. A numerical method
is used to solve for ϱ with a given α, β and δj.
To generate the data, for each type, we first identify
the threshold values of pj and qj based the pre-specified
values of δj, α, β. Second, we identify correlation matrix
∑k (where correlation between each pair of Yj and Zj is
obtained by a numerical method). Multivariate normal
data (Yi1, Zi1,…Yij, Zij,….,Yik, Zik) are generated with
mean zero and correlation matrix ∑k. Then, for each
HPV type, we use the pre-determined threshold values
of pj and qj to dichotomize Yij and Zij to obtain Dij
and Tij.





1 0:91 0:05 0:05 0:05 0:05 0:05 0:05
1 0:05 0:05 0:05 0:05 0:05 0:05
1 0:92 0:05 0:05 0:05 0:05
1 0:05 0:05 0:05 0:05









used to generate the laten vectors.
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